Lynparza extends progression-free survival in gBRCAm metastatic pancreatic cancer
pharmafile | February 26, 2019 | News story | Manufacturing and Production, Sales and Marketing | AstraZeneca, Cancer, MSD, Pancreatic cancer, lynparza, pharma
AstraZeneca and MSD have lifted the curtain on new Phase 3 data for Lynparza (olaparib), confirming that the drug generated a “statistically-significant and clinically-meaningful improvement” in progression-free survival (PFS) compared to placebo as a first-line maintenance monotherapy in germline BRCA-mutated (gBRCAm) metastatic pancreatic cancer in patients whose disease has not progressed on platinum-based chemotherapy.
According to the pair, the data make Lynparza the first PARP inhibitor to demonstrate benefit in this indication at Phase 3.
“This is the first positive Phase 3 trial of any PARP inhibitor in germline BRCA-mutated metastatic pancreatic cancer, a devastating disease with critical unmet need,” commented José Baselga, Executive Vice President, Research and Development, Oncology at AstraZeneca. “The results of POLO provide further evidence of the clinical benefit of Lynparza across a variety of BRCA-mutated tumour types. We will discuss these results with global health authorities as soon as possible.”
Roy Baynes, Senior Vice President and Head of Global Clinical Development, Chief Medical Officer at MSD added: “Trials like POLO demonstrate the shared commitment of MSD and AstraZeneca to assess treatments for difficult-to-treat cancers. The clinically-meaningful results of this trial potentially support the value of testing for germline BRCA mutations in patients with metastatic pancreatic cancer.”
The pair confirmed that the full findings from the study will be presented at an upcoming medical meeting.
Matt Fellows
Related Content
LGC Group opens $100M Organic Chemistry Synthesis Centre of Excellence
LGC Group, a life sciences company, has opened its new Organic Chemistry Synthesis Centre of …
Anocca secures £32m to advance pancreatic cancer trial
Swedish biopharma Anocca has raised approximately £32m (SEK 440m) to support the early-stage clinical development …
NICE recommends Benralizumab for Rare Form of Vasculitis
The National Institute for Health and Care Excellence (NICE) has recommended AstraZeneca’s benralizumab (Fasenra) as …
